Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-3-1
pubmed:abstractText
Hepatocyte growth factor (HGF) is a multifunctional growth factor with mitogenic, anti-apoptotic and anti-fibrotic activities. In this study, we investigated the effect of administration of recombinant human HGF on pulmonary arterial hypertension. Pulmonary arterial hypertension was induced in rats by a single injection of monocrotaline (MCT) and recombinant human HGF (0.12 mg/day) was administered into the right ventricle cavity using osmotic pumps, which were implanted subcutaneously 21 days after MCT injection. Continuous intravenous delivery of recombinant human HGF for 14 days led to prolonged survival of animals suffering from severe MCT-induced pulmonary arterial hypertension. Although a bolus injection of recombinant human HGF did not affect pulmonary arterial pressure, a 14-day administration of recombinant human HGF attenuated the inflammatory cell infiltrate, matrix accumulation and vascular medial thickening. As a consequence, the pulmonary lumen was enlarged and the pulmonary arterial pressure was significantly reduced. Additionally, continuous administration of recombinant human HGF suppressed lung tissue expression of platelet-derived growth factor, which plays an important role in the development of pulmonary arterial hypertension. These results indicate that recombinant human HGF possibly has a great potential for improving symptoms and altering the clinical course of pulmonary arterial hypertension.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1791-244X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
497-502
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:21318217-6-Ketoprostaglandin F1 alpha, pubmed-meshheading:21318217-Animals, pubmed-meshheading:21318217-Blood Pressure, pubmed-meshheading:21318217-C-Reactive Protein, pubmed-meshheading:21318217-Constriction, Pathologic, pubmed-meshheading:21318217-Disease Models, Animal, pubmed-meshheading:21318217-Gene Expression Regulation, pubmed-meshheading:21318217-Hemodynamics, pubmed-meshheading:21318217-Hepatocyte Growth Factor, pubmed-meshheading:21318217-Humans, pubmed-meshheading:21318217-Hypertension, Pulmonary, pubmed-meshheading:21318217-Male, pubmed-meshheading:21318217-Monocrotaline, pubmed-meshheading:21318217-Platelet-Derived Growth Factor, pubmed-meshheading:21318217-Pulmonary Artery, pubmed-meshheading:21318217-Rats, pubmed-meshheading:21318217-Rats, Wistar, pubmed-meshheading:21318217-Recombinant Proteins, pubmed-meshheading:21318217-Survival Analysis
pubmed:year
2011
pubmed:articleTitle
Hepatocyte growth factor improves the survival of rats with pulmonary arterial hypertension via the amelioration of pulmonary hemodynamics.
pubmed:affiliation
Digestive Disease and Life-Style Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences, 3-35-1 Sakuragaoka, Kagoshima, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't